How much funding has Prolium Bioscience raised?

Prolium Bioscience has raised $50.0M in total funding, most recently a Series A round.

Who are Prolium Bioscience's investors?

Prolium Bioscience's investors include RTW Investments.

When was Prolium Bioscience founded?

Prolium Bioscience was founded in 2025.

Where is Prolium Bioscience headquartered?

Prolium Bioscience is headquartered in New York City, New York, United States.

What industry is Prolium Bioscience in?

Prolium Bioscience operates in Healthcare, Biotech.

How many employees does Prolium Bioscience have?

Prolium Bioscience has 1-10 employees.

Prolium Bioscience

Depleting Disease, Empowering Health

New York City, United States · Founded 2025 · $50.0M raised

Healthcare

Biotech

Headquarters: New York City, New York
Employees: 1–10
Founded: 2025
Business Model: B2B

Website: proliumbio.com
Total Funding: $50.0M
Last Round: $50.0M Series AMar 2026
Rounds: 1

About

Prolium Bioscience is a New York City-based clinical-stage biotechnology company developing PRO-203, a potential best-in-class bispecific CD20xCD3 T-cell engager for systemic sclerosis and other severe autoimmune diseases. Founded in 2025 and backed by RTW Investments with a $50M Series A, Prolium targets deep B-cell depletion for durable remissions in refractory autoimmune disease.

Summary

Prolium Bioscience is a Healthcare company based in New York City, United States, founded in 2025. It has raised $50.0M in total across 1 round, most recently a $50.0M Series A round in Mar 2026. Investors include RTW Investments.